Memorandum

Date: 6 January 1983

Subject: EPA Reg. No. 239-1513 ORTHO SEVIN DUST
         Caswell #160

From: B. T. Backus
      IRB/TSS

To: Mr. Jay Ellenberger
    Product Manager 12

Registrant: Chevron Chemical Co.
            Ortho Consumer Products Division
            940 Hensley St.
            Richmond, CA  94804-0036

Active Ingredient:
   Carbaryl (1-naphthyl N-methylcarbamate).....10%
Inert Ingredients:............................90%

Background:

The registrant is requesting deletion of the current
label statements "For agricultural use only" and "Do
not store in areas accessible to children." An acute
oral LD50 study has been submitted.

Comments and Recommendations:

1. The acute oral LD50 study received 11-16-82 is
   acceptable.

2. IRB/TSS would have no objection, on the basis of
   hazard to humans and domestic animals, to the
   deletion of the statements "For agricultural use
   only" and "Do not store in areas accessible to
   children" provided the additional labeling
   revisions indicated below are made.

Labeling:

1. A statement similar to the following should be
   added under Hazards to Humans and Domestic Animals:

   May cause eye irritation. Avoid eye contact.

2. Since the technique of inducing vomiting is not in-
   dicated, the IF SWALLOWED statement should be revised
   to something like:

   Call a doctor immediately. Give a large amount
   of water to drink and make person vomit.
-2-

Hopefully, this would indicate the correct sequence of events, and the doctor should be able to give some recommendations as to the method of inducing vomiting, or whether this treatment would be appropriate if the patient is unconscious or convulsing.

Review:

The following study was conducted at the Chevron Environmental Health Center, P.O. Box 1272, Castro and Midway Streets, Richmond, CA 94802. Study was received at EPA 11-16-82, and is in Acc. 248837.


Procedure: Groups of 5 or 10 male SD rats received oral dosages of 1.0, 1.5, 2.2, 2.6, 3.3 or 5.0 g/kg. Groups of 5 or 10 female SD rats received oral dosages of 1.0, 1.5, 2.2 or 3.3 g/kg. Subjects were subsequently observed for 14 days.

<table>
<thead>
<tr>
<th>Dosage Level (g/kg)</th>
<th>M</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>1.5</td>
<td>1/10</td>
<td>4/10</td>
</tr>
<tr>
<td>2.2</td>
<td>1/10</td>
<td>10/10</td>
</tr>
<tr>
<td>2.6</td>
<td>4/10</td>
<td>-</td>
</tr>
<tr>
<td>3.3</td>
<td>4/5</td>
<td>5/5</td>
</tr>
<tr>
<td>5.0</td>
<td>5/5</td>
<td>-</td>
</tr>
</tbody>
</table>

Acute Oral LD50 (male) = 2.9 (2.0-4.3) g/kg
Acute Oral LP50 (female) = 1.6 (0.96-2.6) g/kg

Symptoms: tremors, ocular discharge, fasciculations, hypoactivity, salivation, collapse. Some symptoms noted in all subjects, even at the lowest dosage level.

Statement is made that at necropsy no pathological changes were noted that could be attributed to the test material.

Study Classification: Core Minimum Data (individual weight data, individual necropsy results not reported).

Product Classification: Tox. Cat. III

Byron T. Backus
IRB/TSS

01/06/83